Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

Rekombinanter IL2RA (Basiliximab Biosimilar) Antikörper

Reaktivität: Human, Cynomolgus, Rhesusaffen FACS, IF, IHC, WB, BR Wirt: Human Chimeric unconjugated Recombinant Antibody
Produktnummer ABIN5668050
  • Target Alle IL2RA (Basiliximab Biosimilar) Produkte
    IL2RA (Basiliximab Biosimilar)
    Antikörpertyp
    Recombinant Antibody
    Reaktivität
    Human, Cynomolgus, Rhesusaffen
    Wirt
    • 2
    • 2
    • 1
    Human
    Klonalität
    • 3
    • 2
    Chimeric
    Konjugat
    • 5
    Dieser IL2RA (Basiliximab Biosimilar) Antikörper ist unkonjugiert
    Applikation
    • 5
    • 3
    • 3
    • 3
    • 2
    • 1
    • 1
    Flow Cytometry (FACS), Immunofluorescence (IF), Immunohistochemistry (IHC), Western Blotting (WB), Blocking Reagent (BR)
    Spezifität
    Basiliximab recognises the human IL-2R and binds to the epitope (116)ERIYHFV(122) within the extracellular domain of the CD25 subunit - binding is abolished when 2 or more residues within the epitope are mutated. This epitope overlaps with the interaction site of CD25 and IL-2. CD25 is found in the high-affinity IL-2R (αβγc) - T cells only express CD25 upon activation. IL-2 binding to IL-2R on T cells modulates proliferation and differentiation.
    Kreuzreaktivität
    Cynomolgus, Rhesusaffen
    Produktmerkmale

    OriginalSpeciesName: Human

    OriginalFormat: IgG1

    Aufreinigung
    Purified antibody.
    Reinheit
    > 98 % as determined by SDS-PAGE
    Endotoxin-Niveau
    Endotoxin is < 1.0 EU/mg as determined by the LAL method
    Immunogen
    Basiliximab was prepared by immunizing BALB/c mice with CTC 16 cells.
    Isotyp
    IgG1 kappa
  • Applikationshinweise
    Basiliximab is derived from the murine anti-Tac antibody. For the clinically used format, the variable regions from this antibody were grafted onto the sequence of the human IgG1? constant regions. Basiliximab binding to CD25 competitively blocks the interaction of IL-2R with its ligand IL-2 on the surface of T cells. Blocking this interaction prevents T cell replication and T cell-mediated B cell activation. Basiliximab binding suppresses the immune system inhibits the pathway activating the cellular immune response to allograft rejection. IL-2 signalling suppression can additionally prevent acute graft-versus-host disease, autoimmune disorders and malignancies such as T cell leukemias (Binder et al, 2007). Basiliximab has also been used in FC, IF, IHC and WB studies, which enables the detection of CD25.
    Kommentare

    NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This is a chimeric antibody created for improved compatibility with existing reagents, assays and techniques.

    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Buffer
    PBS with 0.02 % Proclin 300.
    Konservierungsmittel
    ProClin
    Vorsichtsmaßnahmen
    This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Lagerung
    4 °C,-20 °C
    Informationen zur Lagerung
    Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
  • Target
    IL2RA (Basiliximab Biosimilar)
    Abstract
    IL2RA (Basiliximab Biosimilar) Produkte
    Synonyme
    CD25 antikoerper, IDDM10 antikoerper, IL2R antikoerper, TCGFR antikoerper, IL2RAC antikoerper, Il2r antikoerper, Ly-43 antikoerper, interleukin 2 receptor subunit alpha antikoerper, interleukin 2 receptor, alpha chain antikoerper, IL2RA antikoerper, Il2ra antikoerper
    Hintergrund
    Interleukin-2 receptor subunit alpha, IL-2 receptor subunit alpha, IL-2R subunit alpha, IL-2-RA, IL2-RA, TAC antigen, p55, CD25.
    UniProt
    P01589
Sie sind hier:
Kundenservice